Wojewodzki Szpital Specjalistyczny Im. Janusza Korczaka W Slupsku Sp. z o.o.

The Oddzial Hematologiczny at Wojewodzki Szpital Specjalistyczny Im. Janusza Korczaka W Slupsku Sp. z o.o. is active in research on hemic and lymphatic diseases, with a strong focus on multiple myeloma, lymphoma, and chronic lymphocytic leukemia. These studies are designed to test new treatment approaches and compare them with current standard care to improve disease control and patient outcomes.

• Relapsed or refractory multiple myeloma and treatment effectiveness
• Diffuse large B-cell lymphoma and other B-cell lymphomas
• Chronic lymphocytic leukemia and improved first-line therapy options
• Follicular lymphoma and better disease management strategies

Much of the work at this site centers on evaluating whether newer combinations can extend survival, deepen responses, or offer safer options for people living with blood cancers.

Clinical trials in neoplasms at this site cover a broad range of cancers, including breast cancer, gastric cancer, gastroesophageal junction cancer, bladder cancer, and prostate cancer. The research aims to improve treatment effectiveness, reduce recurrence, and identify better options for patients with advanced or high-risk disease.

• Breast cancer, including HER2-positive and hormone receptor–positive disease
• Gastric and gastroesophageal junction cancers
• Bladder cancer, including muscle-invasive and high-risk non-muscle-invasive disease
• Prostate cancer and longer-term treatment benefit

Research at Slupsk also includes studies in melanoma and lung cancer, reflecting a wide oncology portfolio focused on testing new therapies and comparing them with established treatment standards.

The site is involved in studies within respiratory tract diseases, especially non-small cell lung cancer and small cell lung cancer. These trials are exploring whether new cancer therapies can improve survival and disease control for patients with advanced or metastatic lung cancer.

• Non-small cell lung cancer, including advanced and metastatic disease
• Extensive-stage small cell lung cancer
• Comparisons against current standard cancer treatments
• Studies aimed at improving outcomes in difficult-to-treat lung cancers

Several projects also examine therapies linked to immune system diseases and cancer-related immune responses, showing a strong interest in treatments that may work through more targeted or immune-based mechanisms.

Research in immune system diseases and hemic and lymphatic diseases includes studies on immune thrombocytopenia, polycythemia vera, myelofibrosis, and related marrow disorders. The main goal is to improve symptom control, restore healthier blood counts, and assess the benefit of new therapies for chronic blood conditions.

• Immune thrombocytopenia and platelet response
• Polycythemia vera and reducing the need for phlebotomy
• Myelofibrosis and spleen or symptom improvement
• Long-term management of chronic blood and immune disorders

These studies often focus on whether newer treatments can offer durable benefit while remaining manageable for patients with ongoing hematologic disease.

Although the site is primarily oncology- and hematology-focused, it also participates in research linked to cardiovascular diseases, especially through studies of cancer-associated thrombosis. This work looks at preventing serious clotting events in people receiving cancer treatment, helping address an important complication that can affect safety and quality of life.

• Cancer-associated thrombosis in patients with solid tumors
• Prevention of blood clots during cancer therapy
• Monitoring bleeding risk alongside clot prevention
• Supportive care research for patients with active cancer

At this hospital/clinic site in Poland, the research portfolio combines disease treatment studies with efforts to improve safety and supportive care across a wide range of cancers and blood disorders.